SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-017488
Filing Date
2023-05-15
Accepted
2023-05-15 17:00:49
Documents
67
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1195055
2 ex31-1.htm EX-31.1 19050
3 ex31-2.htm EX-31.2 18685
4 ex32-1.htm EX-32.1 7388
5 ex32-2.htm EX-32.2 7503
  Complete submission text file 0001493152-23-017488.txt   6945931

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mymd-20230331.xsd EX-101.SCH 50166
7 XBRL CALCULATION FILE mymd-20230331_cal.xml EX-101.CAL 50291
8 XBRL DEFINITION FILE mymd-20230331_def.xml EX-101.DEF 274634
9 XBRL LABEL FILE mymd-20230331_lab.xml EX-101.LAB 441442
10 XBRL PRESENTATION FILE mymd-20230331_pre.xml EX-101.PRE 370195
61 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1128658
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36268 | Film No.: 23923950
SIC: 2835 In Vitro & In Vivo Diagnostic Substances